Related references
Note: Only part of the references are listed.Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P. Kalemkerian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
Ibiayi Dagogo-Jack et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
Meng Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Yi-Chen Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Hong Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18F-FDG PET/CT Study
Silvia Morbelli et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
Judith N. Mueller et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
J. H. Chung et al.
ANNALS OF ONCOLOGY (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz et al.
CLINICAL CANCER RESEARCH (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Cecile Jovelet et al.
CLINICAL CANCER RESEARCH (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical Application of Liquid Biopsies
P. Mickey Williams et al.
JAMA ONCOLOGY (2016)
Sampling circulating tumor cells for clinical benefits: how frequent?
Sai Mun Leong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Wei Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
A. D. Nygaard et al.
BRITISH JOURNAL OF CANCER (2014)
Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Sebastien Couraud et al.
CLINICAL CANCER RESEARCH (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Mariam Jamal-Hanjani et al.
PLOS BIOLOGY (2014)
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
Shengri Liao et al.
ACADEMIC RADIOLOGY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Preoperative Staging of Lung Cancer with Combined PET-CT.
Barbara Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Metabolic tumor burden predicts for disease progression and death in lung cancer
Percy Lee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC)
Carlo Greco et al.
LUNG CANCER (2007)
[18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer
R Sasaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection
RJ Downey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)